Literature DB >> 22133796

A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve.

Paul T Finger1, Kimberly J Chin, Lawrence B Tena.   

Abstract

OBJECTIVE: To evaluate slotted eye plaque radiation therapy for choroidal melanomas near the optic disc.
DESIGN: A clinical case series. PARTICIPANTS: Twenty-four consecutive patients with uveal melanomas that were near, touching, or surrounding the optic disc. INTERVENTION: Slotted eye plaque radiation therapy. MAIN OUTCOME MEASURES: Recorded characteristics were related to patient, clinical, and ophthalmic imaging. Data included change in visual acuity, tumor size, recurrence, eye retention, and metastasis.
RESULTS: From 2005 to 2010, 24 consecutive patients were treated with custom-sized plaques with 8-mm-wide, variable-depth slots. Radiation doses ranged from 69.3 to 163.8 Gy (mean, 85.0 Gy) based on delivering a minimum tumor dose of 85 Gy. All treatments were continuously delivered over 5 to 7 days. Mean patient age at presentation was 57 years. Tumors were within 1.5 mm of the optic nerve (n = 3, 13%), juxtapapillary (n = 6, 25%), touching ≥180 degrees (n = 7, 29%), or circumpapillary (n = 8, 33%). Ultrasound revealed dome-shaped tumors in 79% of patients, collar-button tumors in 17% of patients, irregular tumor in 1 patient (4%), and intraneural invasion in 2 patients. Mean initial largest basal dimension was 11.0 mm (standard deviation [SD] ± 3.5 mm; median, 11.4 mm; range, 5.9-16.4 mm). Mean initial tumor thickness was 3.5 mm (SD ± 1.7 mm; median, 3.0 mm; range, 1.4-6.9 mm). Initial visual acuities were a median 20/25 (range, 20/20 to hand motions) and decreased to a median 20/40 (range, 20/20 to no light perception). At a mean follow-up of 23 months, 12 patients required periodic intravitreal bevacizumab to suppress radiation optic neuropathy (RON) or maculopathy. To date, there has been a 100% local control rate. No patients have required secondary enucleation for recurrence or neovascular glaucoma. No patients have developed metastasis.
CONCLUSIONS: Slotted plaque radiation therapy allows peripapillary, juxtapapilary, and circumpapillary choroidal melanomas (and a safety margin) to be included in the radiation targeted zone. Normalization of the plaque position beneath the tumor appears to increase RON and improve local control.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133796     DOI: 10.1016/j.ophtha.2011.08.017

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy.

Authors:  John V Hegde; Tara A McCannel; Colin A McCannel; James Lamb; Pin-Chieh Wang; Darlene Veruttipong; Robert Almanzor; D Jeffrey Demanes; Mitchell Kamrava
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-09       Impact factor: 3.117

2.  Outcomes following Notched Ruthenium-106 Plaque Brachytherapy for Juxtapapillary Choroidal Melanomas.

Authors:  Manvi Manu Sobti; Magdalena Edington; Julie Connolly; David J McLernon; Stefano Schipani; Diana Ritchie; Paul Cauchi; Vikas Chadha
Journal:  Ocul Oncol Pathol       Date:  2021-08-23

3.  Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma.

Authors:  J M Caminal; N Padrón-Pérez; L Arias; C Masuet-Aumatell; C Gutiérrez; J M Piulats; J Pera; J Català; M J Rubio; J Arruga
Journal:  Eye (Lond)       Date:  2016-04-01       Impact factor: 3.775

4.  Optic disc dose reduction in ocular brachytherapy using 125 I notched COMS plaques: A simulation study based on current clinical practice.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  J Appl Clin Med Phys       Date:  2020-07-12       Impact factor: 2.102

Review 5.  Current and emerging treatment options for uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier
Journal:  Clin Ophthalmol       Date:  2013-08-22

Review 6.  Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions.

Authors:  Beatrice Y Brewington; Yusra F Shao; Fredrick H Davidorf; Colleen M Cebulla
Journal:  Clin Ophthalmol       Date:  2018-05-17

Review 7.  Choroidal melanoma: A short review with an Indian perspective.

Authors:  Bikramjit P Pal; Saili Garge; Vikas Khetan
Journal:  Oman J Ophthalmol       Date:  2017 Sep-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.